Welcome
Compassionate, Experienced Animal Lovers Cell & Gene Therapy for pets.
Advancing Veterinary Care
Hello
The Best Pet Cell & Gene Therapy Services Provider - BIovet
We offer a wide range of pet care services, including Cell & Gene Therapy for pets . Our team of experienced professionals is passionate about Advancing Veterinary Care to your furry companions. Let us take care of your pets while you take care of your busy life.
About Us
Therapies
Licensing human validated therapeutic technology
Our advanced therapies have been tested in the clinic and have proven efficacy in humans as well as various animal models
Osteoarthritis: Chronic Joint Inflammation
MSCs Orthopedics
Autologous Products for the Treatment of Osteoarthritis
MSC for Cell Therapy
MSCs Processing Flow
Cellular-Based Treatment For Orthopedic Disorders
Adipose (Fat) Tissue is a Rich Source of Regenerative Cells
Introduction
Cell & Gene Veterinary Field
The market of Cell &
Gene therapies
●Veterinarian biotechnology company specializing in delivering innovative cell and gene therapies to veterinary clinics.
●
●Production on site by state-of-the-art automated systems, ensures the rapid, efficient, and effective supply of its products directly in the clinical setting.
●
●Elevating the standards of veterinary medicine by bringing the revolutionary advancements of cell and gene therapies to the pet care field.
●
●We aim to revolutionize the treatment of blood cancers, dermal problems, and orthopedic issues in animals.
What are Cell & Gene Therapies - CGT
Traditional biopharmaceutical treatments use proteins for therapeutic applications
Cell therapies use manipulated genes and cells for therapeutic applications
Autologous cell and gene therapies use a
patient’s own cells to create the treatment
Up till now limited by cost for veterinary applications – TGI BIOVET CGT is providing a direct solution
Automation
Low-cost via on-site
automated production
Our cutting-edge automated systems streamline the therapy delivery, ensuring the best possible outcomes for our animal patients
Icellator– close collaboration with producer
●Ease of Operation
●Easy-to-use touch screen interface
●Sterile single-use plastic disposable kit
●Small Footprint, Operating Room Compatible
●Icellator2 Point-of-Care Platform Technology
Key Advantages
Cellular processing system semi-automated Purification / Concentration
>100 X concentration of all viruses
Replacing regular concentration
Controlled, continuous and automatic processing
About BIovet CGT
Market
Strategy
Strategy
Positioned to become the market leader
Pet ownership on the rise
Pets are part of the family
Lack of Vet workforce
Replace staff intensive treatments
Demand for advanced therapies
Rising vet spending per pet
$35 billion $60 billion
As of 2023, the global veterinary healthcare market size is approximately $35 billion,
projected to
Positioned to become the market leader
Pet ownership on the rise
Pets are part of the family
Lack of Vet workforce
Replace staff intensive treatments
Demand for advanced therapies
Rising vet spending per pet
$35 billion $60 billion
As of 2023, the global veterinary healthcare market size is approximately $35 billion,
projected to reach $60 billion by 2028, growing at a CAGR of 5.5%.
.
$3.5 billion $6 billion
Our targeted submarket
Veterinary clinics dealing with blood cancers, dermal problems, and orthopedic problems in animals is estimated to constitute approximately 10% of the total market, translating to an initial market size of around $3.5 billion, projected to reach $6 billion by 2028.
Addressing largest pet indications
●Cancer Therapy: Utilizing CGT techniques for the treatment of various blood cancers in animals.
●
●Dermal Therapy: Providing innovative CGT for
a broad range of skin conditions in animals
●Orthopedic Therapy: Applying CGT to enhance bone healing and address various orthopedic issues in animals.
Strategy
Strategy
Strategy
Strategy
Building a clinic-based platform allows quick scale-up
TGI - BioVet CGT– Market entry strategy
•Limited number of Veterinarians to treat the expanding number of companion animals
•Veterinary burnout
•Cost of care for companion animals is increasing
•Focus on episodic care
•Petovations™ Pet Innovations Health Platform
•Treat every
Strategy
Building a clinic-based platform allows quick scale-up
TGI - BioVet CGT– Market entry strategy
•Limited number of Veterinarians to treat the expanding number of companion animals
•Veterinary burnout
•Cost of care for companion animals is increasing
•Focus on episodic care
•Petovations™ Pet Innovations Health Platform
•Treat every pet individually and design personalized care
•Technology-driven early intervention
•Treat the underlying cause of the disease before they clinically manifest themselves and not the symptoms
•Decreased Pet loss of life (cost & social impact)
•Increased pet parent satisfaction
•Streamlined care instruction, education, ongoing pet wellness via application
•Integration of innovative therapies
•Lower TCOC (Total Cost of Care) than conventional models
Cell therapy centers for veterinary use
The Biovet CGT partnership offers a wide variety of cellular derived therapies, complies to the highest regulatory standards. The leading technologies includes:
•Mesenchymal Stem Cells (MSCs) for orthopedic disorders •Dermatology treatments •Cellular-based cancer immunotherapies
Suggested therapies provide solution where common veterinary practice fails, integrate swiftly into any selected facility and easily regulated
Value
Strategy
Value
Steps for building value
A combined licensing and partnering strategy
Production
Automated production by clinical staff
Therapies
Patented Therapies From Medlab
Market
Market entry through Major Pet Store chain